EZH2 and diffuse large B-cell lymphoma: The interim results of phase II clinical trial showed a significant increase in ORR in DLBCL and follicular lymphoma patients with EZH2 mutant compared with wild-type (40% vs. 18%;63% vs. 28%) [194, 195].